Regulacje i polityka gospodarcza · 28/12/2020

National Cancer Institute to Grant Exclusive Patent License for CAR Therapy for FLT3 Expressing Malignancies

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to Senti Bio for the development and commercialization of CAR therapies using natural killer cells for treating FMS-Like Tyrosine Kinase 3 expressing malignancies.